A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Non-small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Colorectal Carcinoma|Pancreatic Adenocarcinoma|Breast Cancer|Other Solid Tumors
Interventions: BIOLOGICAL: Autologous, engineered T Cells targeting TP53 R175H
Sponsor: Neogene Therapeutics, Inc.